Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1223 | D-dimer,CBC.ESR,CRP, Wiki | 0.45 |
| drug1637 | Facial mask Wiki | 0.45 |
| drug494 | BI 1015550 Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1613 | FFP2 Wiki | 0.45 |
| drug4804 | [18F]FP-R01-MG-F2 Wiki | 0.45 |
| drug941 | Centricyte 1000 Wiki | 0.45 |
| drug2460 | MFS Wiki | 0.45 |
| drug2906 | ORIN1001 Wiki | 0.45 |
| drug2357 | Liver function tests ,serum ferritin and PCR for COVID-19 . Wiki | 0.45 |
| drug2050 | IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki | 0.45 |
| drug2333 | Liberase Enzyme (Roche) Wiki | 0.45 |
| drug4156 | Sterile Normal Saline for Intravenous Use Wiki | 0.45 |
| drug2611 | Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki | 0.45 |
| drug4259 | TD-1058 Wiki | 0.45 |
| drug3195 | Placebo Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011658 | Pulmonary Fibrosis NIH | 0.53 |
| D011649 | Pulmonary Alveolar Proteinosis NIH | 0.45 |
| D015209 | Cholangitis, Sclerosing NIH | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005355 | Fibrosis NIH | 0.38 |
| D002761 | Cholangitis NIH | 0.32 |
| D017563 | Lung Diseases, Interstitial NIH | 0.12 |
| D008171 | Lung Diseases, NIH | 0.08 |
| D011024 | Pneumonia, Viral NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002206 | Pulmonary fibrosis HPO | 0.53 |
| HP:0006517 | Intraalveolar phospholipid accumulation HPO | 0.45 |
| HP:0030151 | Cholangitis HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006515 | Interstitial pneumonitis HPO | 0.12 |
| HP:0002088 | Abnormal lung morphology HPO | 0.08 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 5 clinical trials
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
Description: The SUVmax in a lung or liver with known IPF, COVID19 pneumonia, or PSC respectively will be compared to the SUVmax in a known healthy lung/liver. It is expected that the SUV max, which is a measurement of the maximum value of radiopharmaceutical uptake within the region of interest (ROI) in IPF, COVID19 pneumonia, and PSC will be higher than the SUV max in the healthy lung/liver.
Measure: SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung Time: an estimated average of 2 hoursDescription: Blood samples for blood time-activity measurements taken at 1, 3, 5, 10, 30, and 60 minutes after tracer injection for tracer kinetic analysis. Tracer kinetic analysis shows radiopharmaceutical distribution from the blood to the tissues over time.
Measure: Time Activity Measurements Time: an estimated average of 1 hoursDescription: EKG data, vital signs and laboratory data collected before IV injection of [18F]FP-R01-MG-F2 and after completion of the scan will allow the investigators to evaluate the safety and tolerability of the radiopharmaceutical. This will be measured as the number of patients who successfully completed the study.
Measure: Incidence of Study Completion (Safety and Tolerability) Time: an estimated average of 2 hoursCOVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs.
Description: Reporting of Adverse Events or Severe Adverse Events Assessed by CTCAE v4.0
Measure: Incidence of Treatment-Emergent Adverse Events Time: 1 monthDescription: High Resolution Computerized Tomography of Lung (HRCT Lung) for Fluidda Analysis comparative at baseline and 3 and 6 months post-treatment comparative analytics
Measure: Pulmonary Function Analysis Time: baseline, 3 Month, 6 monthsDescription: Finger Pulse Oximetry taken before and after 6 minute walk on level ground, compare desaturation tendency
Measure: Digital Oximetry Time: 3 months, 6 monthsTo investigate the efficacy of BI 1015550 compared to placebo based on the change from baseline in Forced Vital Capacity (FVC). To investigate safety and tolerability of BI 1015550 in the overall trial population.
This is a Phase 1, 3-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution. Part A is a SAD study in healthy subjects, Part B is a MAD study in healthy subjects, and Part C is a multiple-dose study in subjects with IPF.
Description: Number and severity of treatment emergent adverse events
Measure: Part A (SAD) - Adverse Events Time: Part A (SAD) Day 1 to Day 8Description: Number and severity of treatment emergent adverse events
Measure: Part B (MAD) - Adverse Events Time: Part B (MAD) Day 1 to Day 21Description: Number and severity of treatment emergent adverse events
Measure: Part C (IPF) - Adverse Events Time: Part C (IPF) Day 1 to Day 35Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)
Measure: Pharmacokinetics (PK) of TD-1058: AUC Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Maximum observed concentration (Cmax)
Measure: Pharmacokinetics (PK) of TD-1058: Cmax Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)
Measure: Pharmacokinetics (PK) of TD-1058: Tmax Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib). A maximum of 24 evaluable subjects will be required to complete the study. The study will consist of 3 dose cohorts each enrolling a maximum of 8 subjects randomized either to the active (5 subjects) group or placebo (3 subjects) group. Each subject will receive daily oral doses of ORIN1001 or placebo for 28 days. The safety and pharmacokinetic profile will be evaluated in this study and will include cardiovascular and pulmonary endpoints.
Description: measurement of blood pressure
Measure: Blood pressure Time: Up to 60 daysDescription: measurement of heart rate
Measure: Heart Rate Time: Up to 60 daysDescription: Measurement of respiratory rate
Measure: Respiratory Rate Time: Up to 60 daysDescription: Measurement of body temperature
Measure: Body Temperature Time: Up to 60 daysDescription: Cardiovascular evaluation to determine intervals including QTc interval
Measure: 12-lead ECG Time: Up to 60 daysDescription: ALT, albumin, ALP, AST, BUN, Ca, Cl, Cholesterol, Creatinine, CK, CA, Elastase, GGT, glucose, HDL, LDH, lipase, LDL, phosphorus, sodium, Total bilirubin, Total protein, Triglycerides, Uric acid, Lipid panel
Measure: Serum Clinical Chemistry analysis Time: Up to 60 daysDescription: WBC, RBC, Hb, HCT, MCV, MCH, MCHC, Neu, Lymphocytes, EOS, Bas, PLT
Measure: Whole blood Hematology analysis Time: Up to 60 dysDescription: PT, APTT, INR
Measure: Whole blood Coagulation Parameters Time: Up to 60 daysDescription: Bilrubin, glusoe, ketones, leukocytes, nitrite, blood, pH, specific gravity, protein, urobilinogen
Measure: Urinalysis Time: Up to 60 daysDescription: Evaluation of other medications taken currently with investigative drug
Measure: Concomitant medications Time: Up to 60 daysDescription: Medical Health examination, medical history, medicine history, reproductive history, baseline information
Measure: Physical examination Time: Up to 60 daysDescription: Body weight in kg
Measure: Body weight Time: Up to 60 daysDescription: Pulmonary Function Tests: Forced vital capacity (FVC), Forced expiratory volume (FEV)
Measure: Spirometry Time: Up to 60 daysDescription: Height in cm
Measure: Height Time: Up to 60 daysDescription: Calculation of BMI using weight (kg) and height (cm)
Measure: Body mass index (BMI) Time: Up to 60 daysDescription: Lung test to assess diffusion capacity
Measure: DLCO - Assessment of diffusion capacity Time: Up to 60 daysDescription: Blood collection for evaluation of ORIN1001 exposure. Measurements will assess half life, exposure, maximum concentration, time to maximum concentration and accumulation ratios
Measure: Blood collection to measure drug concentration over time Time: Up to 29 daysDescription: Blood collection for evaluation of disease biomarker of lung fibrosis: SP-D, MMP-7 and KL6. Specific biomarker to be determined
Measure: Exploratory biomarkers to evaluate lung fibrosis Time: Up to 60 daysDescription: Questionnaire to assess the quality of life during the study period
Measure: Quality of Life Questionnaire Time: Up to 60 daysDescription: Blood collection for evaluation of inflammation such as cytokines TGF-B and/or IL-6
Measure: Exploratory biomarkers to evaluate inflammation Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports